Income Statement
THERAVANCE BIOPHARMA, INC.
TBPH
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
107.46 | 64.38 | 57.42 | 51.35 | 205.00 | 73.09 | 240.00 | 60.37 | 15.39 | 48.65 | 42.13 | 11.69 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
107.46 | 64.38 | 57.42 | 51.35 | 205.00 | 73.09 | 240.00 | 60.37 | 15.39 | 48.65 | 42.13 | 11.69 |
|
Operating Expenses
|
111.07 | 111.33 | 113.46 | 143.30 | 313.10 | 369.61 | 325.33 | 299.12 | 275.51 | 229.12 | 224.03 | 244.23 |
|
Research & Development
|
37.41 | 37.64 | 40.62 | 63.39 | 193.66 | 260.95 | 219.25 | 201.35 | 173.89 | 141.71 | 129.17 | 168.52 |
|
Selling, General & Administrative
|
73.65 | 69.17 | 70.10 | 67.07 | 99.30 | 108.66 | 106.08 | 97.06 | 95.59 | 84.51 | 90.20 | 71.65 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-3.60 | -46.95 | -56.04 | -91.96 | -108.10 | -296.53 | -85.33 | -238.75 | -260.12 | -180.47 | -181.90 | -232.54 |
|
Non-Operating Income
|
-132.85 | -2.34 | -6.77 | 0.86 | 91.48 | -9.99 | 156.35 | -12.67 | 11.59 | 4.63 | -0.63 | -1.87 |
|
Interest Income
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | 2.35 | 6.37 | 46.89 | 44.59 | 31.86 | 10.48 | 8.55 | 1.40 | - | - |
|
Other Non-Op Income / Expense
|
10.17 | 4.88 | 9.12 | 53.24 | 103.99 | 68.44 | 33.71 | 11.18 | 4.96 | 1.31 | 0.63 | 1.87 |
|
Income Before Tax
|
129.25 | -44.61 | -49.27 | -92.82 | -0.23 | 37.57 | 11.78 | 14.84 | -0.10 | 23.32 | -1.22 | 4.63 |
|
Income Tax Expense
|
23.35 | 11.80 | 5.92 | -964.95 | -0.15 | -8.52 | -5.22 | -10.56 | -271.71 | 5.57 | 0.95 | -230.67 |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
105.90 | -56.42 | -55.19 | 872.13 | -199.43 | -278.02 | -236.46 | -215.52 | 0.00 | -190.67 | -182.22 | 0.00 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-3.60 | -46.95 | -56.04 | -91.96 | -108.10 | -296.53 | -85.33 | -235.59 | -256.10 | -177.35 | -178.91 | -229.88 |
|
Earnings Per Share (Basic)
|
2.10 | -1.15 | -1.00 | 11.85 | -2.87 | - | - | - | - | - | - | - |
|
Diluted EPS
|
2.06 | -1.15 | -1.00 | 11.85 | -2.87 | - | - | - | - | - | - | - |
|
Weighted Average Shares
|
50.32 | 48.85 | 55.30 | 73.59 | 69.46 | 62.81 | 56.45 | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
51.51 | 48.85 | 55.30 | 73.59 | 69.46 | 62.35 | 55.61 | - | - | - | - | - |
|
Comprehensive Income
|
105.95 | -56.35 | -55.24 | 872.12 | -199.47 | -278.12 | -236.14 | -214.96 | -285.89 | -190.85 | -182.21 | -237.21 |